The goal of this work was to verify whether the superiority of the sirolimus-eluting stent (SES) in inhibiting neointimal hyperplasia could be demonstrated in complex coronary lesions.
Both the sirolimus-eluting stent (SES) (Cypher, Cordis, Miami Lakes, Florida) (1,2) and the paclitaxel-eluting stent (PES) (Taxus, Boston Scientific, Natick, Massachusetts) (3) have shown a striking reduction in neointimal hyperplasia compared with bare-metal stents based on angiographic assessments. However, 2-dimensional angiography only depicts luminal characteristics of vessels. Volumetric intravascular ultrasound (IVUS) provides unique information regarding the vascular responses to stent implantation. In particular, IVUS allows quantification of neointimal hyperplasia and of vessel remodeling (2) . Few data are available on IVUS assessment of long, complex coronary lesions treated with the SES or the PES, and to date no randomized comparison of IVUS findings has been reported in these subjects. A comparison of IVUS reports involving short lesions treated with the SES (4 -8) or the PES (3, 9, 10) shows that the SES appears to exert a more powerful inhibition of neointimal growth. The objective of this study was to verify whether the superiority of the SES in inhibiting neointimal hyperplasia could be demonstrated in complex coronary lesions.
Methods

Patient selection.
Patients with stable angina, non-STsegment elevation acute coronary syndrome, or documented silent ischemia undergoing coronary angiography at Pisa Uni-versity Hospital were screened for enrollment. Inclusion criteria were: 1) presence of an angiographically significant stenosis in the proximal and/or mid-portion of the left anterior descending artery; 2) American College of Cardiology/American Heart Association lesion class B2 or C, requiring a stent Ն16 mm in length; 3) vessel reference diameter between 2.5 and 3.7 mm at lesion site; and 4) consent to undergo a follow-up angiography at 9 months. Exclusion criteria were: 1) ST-segment elevation acute myocardial infarction; 2) intolerance to aspirin or clopidogrel; 3) severe comorbidity; and 4) participation in another clinical study. The study complied with the Declaration of Helsinki and was approved by the local ethics committee. All patients gave written informed consent. Randomization and treatment. Randomization was performed after diagnostic angiography and before angioplasty. Sequentially numbered, sealed randomization envelopes were used, with a computer-generated random allocation sequence. Patients were randomized on a 1:1 basis to treatment with an SES (Cypher) or a PES (Taxus). Stent diameter ranged from 2.75 to 3.50 mm; minimum stent length was 18 mm for the SES and 16 mm for the PES. Shorter stents could be used as a second stent for complete lesion coverage, or to treat edge dissection. In case of inability to deliver a single stent to cover the whole length of the lesion, the use of 2 shorter stents with overlapping edges was allowed. If a mixture of drug-eluting stents could not be avoided, the patient was excluded from the study.
Before percutaneous coronary intervention (PCI), all patients received Ն100 mg of aspirin, and a 300-mg loading dose of clopidogrel was administered before or at the time of PCI. Percutaneous coronary intervention was performed using a standard technique with unfractionated heparin (70 U/kg of body weight). Use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Successful intervention was defined as a patent vessel with antegrade Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 and angiographic residual stenosis Ͻ50%. Patients were discharged on aspirin 100 mg daily indefinitely, and clopidogrel 75 mg daily for Ն6 months after PCI. In addition, all patients were discharged on simvastatin indefinitely, at a daily dose of 20 or 40 mg, as necessary to obtain low-density lipoprotein cholesterol levels of Ͻ110 mg/dl. IVUS analysis. A commercially available IVUS system (Boston Scientific) was used. All IVUS studies were performed at the end of the procedure, after the intracoronary administration of nitroglycerin 200 g. The IVUS catheter was advanced at least 10 mm distal to the stent, and imaging was performed to at least 10 mm proximal to the stent, with a motorized transducer pullback speed of 0.5 mm/s. Intravascular ultrasound images were recorded onto S-VHS tape and analyzed by 2 expert readers blinded to the treatment arm, with intraobserver and interobserver agreements of r ϭ 0.96 and r ϭ 0.91, respectively. The interobserver variability was assessed comparing the measurement of lumen volume in 15 recordings. Intraobserver variability was assessed by reanalyzing 15 recordings 1 month after the initial analysis. Intravascular ultrasound characteristics were identified according to the criteria of the American College of Cardiology Clinical Expert Consensus document on IVUS (11), using computerized planimetry (Tapemeasure, Indec Inc., Mountain View, California).
The external elastic membrane, stent, and lumen contours were identified, both at baseline and follow-up, every millimeter within the stented segment by semiautomatic detection contour mode. When the external elastic membrane could not be identified (due to acoustic shadowing) over a Ͼ90°arc, it was not measured. If the external elastic membrane could not be measured in Ͼ75% of the stent length, the patient was excluded from the study. The total vessel volume, stent volume, and lumen volume were measured, and the mean vessel area, mean stent area, and mean lumen area were calculated as the ratio of the corresponding volume to the analyzed length. The minimal lumen area (MLA) was also measured. The length of each stent that was free of IVUS-detectable neointimal hyperplasia was determined. The following parameters were calculated: mean peristent plaque area (PSPA) ( (12) . Incomplete stent apposition was defined as a separation of at least 1 stent strut from the intimal surface of the arterial wall. Incomplete apposition at 9 months was considered "persistent" if already present post-procedure, and "late-acquired" if it was not present after implantation (13) . Quantitative coronary angiography. Coronary angiograms at baseline, immediately after PCI, and at follow-up were performed in at least 2 orthogonal views after intracoronary administration of nitroglycerin 0.2 mg. Care was taken to avoid vessel overlapping and to obtain the same views at baseline and follow-up. Angiograms were analyzed by 2 experienced readers, unaware of treatment allocation, with the use of an automated edge-detection system (Quantcor Siemens System, Siemens AG, Erlangen, Germany). The intraobserver and interobserver agreements were r ϭ 0.95 and r ϭ 0.88, respectively. The interobserver variability was assessed comparing the measurement of minimal lumen diameter in 15 angiograms. Intraobserver variability was Major adverse cardiac events were assessed at 9 months, but were not an end point. They included death from cardiac causes, myocardial infarction, and target-lesion revascularization. Myocardial infarction was defined as an increase in creatine kinase to more than twice the upper limit of the normal range, with elevation of troponin I. Target-lesion revascularization was defined as revascularization for a stenosis within the stent or its 5-mm borders. Statistical analysis. At the time of study design, IVUS data on the SES and the PES in the literature involved short coronary lesions in small populations, with a NIHA% of 6.6 Ϯ 5.5% for the SES (5), and of 7.8 Ϯ 9.9% (0.7 Ϯ 0.9 mm 2 ) for the PES (3). Since total stented length increases the risk of in-stent restenosis also for drug-eluting stents (14), we anticipated a 60% increase in NIHA% in long, complex lesions. Thus, a NIHA% of 9 Ϯ 5% and of 13 Ϯ 7% with the SES and the PES, respectively, was anticipated. Consequently, a total of 74 patients provided 81% power to detect a 4% absolute difference in NIHA%, with a significance level of 0.05. Allowing for 25% attrition due to lack of follow-up angiography and insufficient IVUS quality, we calculated that 100 patients would need to be enrolled.
Data are presented as frequencies or mean Ϯ SD. Comparisons between the SES and the PES were performed with the 2-tailed, unpaired t test or the MannWhitney test for continuous parameters, the paired t test for change from post-procedure to follow-up, and the Fisher exact test for categorical variables. Correlations between NIHA and PSPA% post-procedure and between angiographic LL and NIHA% were performed by linear regression analysis. Significance was set at an alpha of 0.05. (Tables 1 and 2 ). The degree of coronary atherosclerosis was indicated by the high prevalence of multivessel disease (75.3%), previous myocardial infarction (30.6%), and diabetes mellitus (24.7%), and by lesion length (mean 20.6 Ϯ 9.4 mm, range 12 to 49 mm). A trend toward a larger RVD in the PES group was found (p ϭ 0.09).
Results
Between
Procedural characteristics, including the number of stents per lesion, stent diameter and length, and the rate of direct stenting, were also similar between the 2 groups ( Table 2) . Delivery of the single long stent initially chosen failed in 2 SES and 1 PES patients (p Ͼ 0.2). IVUS results. Mean vessel, stent, and lumen areas were similar in the SES and PES groups, both after stent implantation and at 9-month follow-up (Table 3 ). The changes in mean vessel, plaque, and lumen areas at follow-up are represented in Figure 2 . Mean lumen area showed a significant reduction in both groups (p ϭ 0.004 and p Ͻ 0.001, for the SES and PES groups, respectively), related to the development of neointimal hyperplasia. The reduction in lumen area at follow-up was significantly higher in the PES group (p ϭ 0.002). Conversely, NIHA and NIHA%, the primary end point of the study, were significantly smaller in the SES group (p Ͻ 0.001). The stent length free of IVUS-detectable neointimal hyperplasia was significantly shorter in the PES group (p Ͻ 0.001). More than 75% of stent length was neointimal hyperplasiafree in 59.5% of SES versus 25.6% of PES (p ϭ 0.002), while less than 25% of stent length was neointimal hyperplasia-free in 9.5% of SES versus 41.9% of PES (p ϭ 0.001). Neointimal hyperplasia-free stent length was inversely correlated with NIHA% in both SES and PES (p Ͻ 0.001) (Fig. 3) .
Mean vessel area and PSPA in the SES group showed a trend toward a reduction at follow-up (p ϭ 0.14 and p ϭ 0.09, respectively), while in the PES group they showed no significant change (Table 3 , Fig. 2 ). In terms of PSPA%, the reduction in the SES group from post-procedure to follow-up reached statistical significance (p ϭ 0.008), making the mean change in PSPA% from post-procedure to follow-up significantly different between the SES and PES groups (Ϫ2.1 Ϯ 4.8% vs. 0.1 Ϯ 3.4%, respectively; p ϭ 0.01). No correlation was found between NIHA at follow-up and PSPA% post-procedure (r ϭ 0.062, p Ͼ 0.2).
An in-stent MLA of Ͼ6 mm 2 after implantation (72.6% vs. 74.4%, in SES and PES groups, respectively; p Ͼ 0.2) was associated with no target-lesion revascularization during follow-up (0% vs. 9.2%; p ϭ 0.06), and with minimal binary in-stent restenosis (1.6% vs. 13.6%; p ϭ 0.05), compared with an in-stent MLA Յ6 mm 2 . Incomplete stent apposition was comparable in the SES and PES groups, both after implantation (7.1% vs. 9.3%, respectively; p Ͼ 0.2) and at 9 months (14.3% vs. 11.7%; p Ͼ 0.2), being persistent in 4.8% versus 4.7% of patients in the SES and PES groups, respectively (p Ͼ 0.2), and late-acquired in 9.5% versus 7.0% (p Ͼ 0.2). Incomplete apposition was never associated with a major adverse cardiac event.
Angiographic results. The mean in-stent LL at follow-up was 0.16 Ϯ 0.19 mm in the SES group and 0.32 Ϯ 0.33 mm in the PES group (p ϭ 0.003) ( Baseline Angiographic Characteristics and Procedural Results 
Discussion
Not surprisingly, in light of previous angiographic and clinical studies in short lesions, the present study demonstrates that the SES reduces neointimal tissue proliferation significantly more than the PES in long, complex coronary lesions. However, the NIHA% was remarkably low for both types of drug-eluting stents, compared with previous data on bare-metal stents (30% to 40%) (10, 15) , and in agreement with previously reported IVUS data on the SES (2,4 -8) and the PES (3, 9, 10, 16, 17) . In particular, in our SES population, with a mean lesion length 21.2 mm, the NIHA% was 7.4%, which is higher Intravascular Ultrasound Measurements Angiographic Results at Follow-Up Abbreviations as in Table 1 .
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than that reported with SESs for shorter lesions at 8 to 12 months follow-up: 2.3% was reported in the first series from São Paulo, Brazil (mean lesion length 12.9 mm) (4), 1% in the RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial (mean lesion length of 14.4 mm) (7), 1.2% in the E-SIRIUS (European Sirolimus-Eluting Stent in Coronary Lesions) trial (mean lesion length of 15.5 mm) (18) , and 3.1% in the SIRIUS (Sirolimus-Eluting Stent in Coronary Lesions) trial (mean lesion length of 14.4 mm) (2) . Interestingly, in the first series by São Paulo, NIHA% appeared to increase to 6.6% at 2 years follow-up (5), and to 7.9% at 4 years (6).
Regarding the PES, in our population with mean lesion length 20.1 mm, the NIHA% (15.4%) was higher than the 7.8% reported in the TAXUS-II trial with a mean lesion length 10.6 mm (3), but similar to the 12.2% of the TAXUS-IV trial (mean lesion length 12.5 mm) (10) , and the 13.1% of the TAXUS-V trial (mean lesion length 17.3 mm) (17) .
The present study describes, for the first time in the literature, a direct comparison of IVUS results after SES and PES implantation for long lesions. Most published IVUS reports involve short lesions treated with a single SES (4 -8) or PES (3,9,10). Fewer IVUS data involve more complex lesions, with use of multiple SESs (2, 18) or PESs (17) . The only randomized comparison of the SES and the PES in complex lesions, the CORPAL (Drug-Eluting Stent for Complex Lesions) trial, has only been presented orally (19) .
The length of stent free of IVUS-evident neointimal hyperplasia has been reported to be greater in a nonpolymeric PES than in the corresponding bare-metal stent, and to correlate inversely with NIHA% (20) . In the present study, the inverse correlation with NIHA% was confirmed both for Cypher and Taxus stents (p Ͻ 0.001). Interestingly, the mean neointimal hyperplasia-free stent length in SES was almost double than in PES (p Ͻ 0.001), and IVUS-detectable neointimal hyperplasia was observed in over 75% of stent length in 41.9% of PES versus only 9.5% of SES (p ϭ 0.001). Thus, neointimal hyperplasia inside PES is often represented along the entire stent length, while SES appear neointimal hyperplasia-free for most of their length. However, since the assessment of stent endothelization is below the resolution of IVUS (20) , the absence of IVUS-detectable hyperplasia does not imply the absence of re-endothelization.
There was no correlation between neointimal hyperplasia and post-procedural peri-stent plaque burden in our study. This finding is in agreement with previous reports showing that suppression of neointimal proliferation occurs irrespective of residual plaque burden after procedures with both the SES (21) and the PES (9) . Late-acquired incomplete stent apposition was infrequent in both the SES and PES groups (9.5% vs. 7.0%, p Ͼ 0.2) in the current study, which is consistent with a recent large, retrospective study by Hong et al. (22) , indicating a prevalence of 13.2% with the SES and 8.4% with the PES in a real-world population. The number of patients with late-acquired incomplete stent apposition in our study was too small to draw any conclusions about its possible mechanism or clinical relevance.
Although the absolute changes in vessel and plaque area from baseline to follow-up in the current study were small and did not reach statistical significance, the reduction in PSPA% in the SES group was significant. This finding is in contrast with previous reports showing no such variations at 6-month follow-up (7, 8) . However, at 4-year follow-up after SES implantation, a significant negative vessel remodeling behind the stent struts has been described (23) . With regard to PES, we did not observe significant changes in PSPA%, which is in agreement with the TAXUS-IV trial (10) . On the contrary, an IVUS subanalysis of the TAXUS-II trial showed a significant increase in PSPA at 6 months (9), although this increase regressed at 2-year follow-up (16) .
In our opinion, factors other than the stent-eluted drug may play a major role in peri-stent plaque changes. We recently demonstrated that treatment with simvastatin 20 mg/day in normocholesterolemic patients undergoing baremetal stent implantation significantly reduces PSPA% compared with placebo (Ϫ14% vs. ϩ6%) (15) . This observation, together with the apparent clinical benefits of statin treatment, underlies the aggressive lipid-lowering approach (aiming for an low-density lipoprotein cholesterol level Ͻ110 mg/dl) we routinely use with all patients undergoing coronary interventions. At follow-up, 93% of SES patients and 95% of PES patients were on statins. Statin treatment may play a role in the observed reduction in PSPA% in the SES group in our study, and may mask the positive remodeling tendency described with the PES in the TAXUS II trial (3).
An MLA Ͼ6 mm 2 has been reported to reduce the risk of target-lesion revascularization and qualifies as an "optimal IVUS result" (12) . In our SES and PES populations, an MLA Ͼ6 mm 2 post-procedure was associated with a very low rate of angiographic binary in-stent restenosis (1.6% vs. 13.6%; p ϭ 0.05), and with no need for target-lesion revascularization during follow-up.
In agreement with the IVUS findings, quantitative angiography in our study showed a significantly lower LL with the SES than the PES (0. (26) . Angiographic restenosis rates in the present study were also similar to those reported in the literature, but the population size was too small to allow meaningful considerations. The present study was not powered to detect differences in clinical end points; however, the rate of major adverse cardiac events was low and comparable between the 2 groups. Our data confirm the results of subgroup analyses of patients with a stenosis in the left anterior descending artery in the SIRIUS (27) and TAXUS-IV (28) trials, showing a 1-year binary in-stent restenosis rate of 2.0% and 8.7%, respectively, and a target-lesion revascularization rate of 6.0% and 5.8%, respectively. In a recent meta-analysis of 6 randomized trials comparing the clinical and angiographic outcome of SES and PES implantation, Kastrati et al. (29) concluded that patients receiving the SES have a significantly lower risk of restenosis and target-vessel revascularization. However, until results of a multicenter study with an adequately powered clinical end point are available, the SES and the PES should be considered clinically equivalent.
This study is limited by the absence of an IVUS core lab. However, we perform an average of 150 IVUS examinations per year, thus providing reliable expertise in the evaluation of IVUS images. Secondly, the identification of the external elastic membrane beyond the stent struts can be difficult or even impossible due to acoustic shadowing and presence of side branches, making the measurement of vessel volumes unreliable. In order to improve the quality of our data, we excluded those patients in whom the external elastic membrane could not be identified in Ͼ75% of stent length, and calculated the mean vessel area as the ratio of vessel volume to the actually analyzed length. We also acknowledge that the inclusion of patients with acute coronary syndromes and the discretional administration of glycoprotein IIb/IIIa inhibitors may have had confounding effects on neointimal proliferation. Finally, the sample size was too small to compare the clinical outcome, which was not an end point of the study, but it was adequate for the prespecified comparison of neointimal hyperplasia.
Whether or not the use of the SES (with the lower neointimal hyperplasia formation) provides superior clinical outcomes in the prognostically important left anterior descending artery cannot be answered in this study but is certainly an area deserving further investigation in future studies.
Conclusions. The present study demonstrates that both the SES and the PES cause limited neointimal hyperplasia in complex lesions, with a significant difference in favor of the SES. Comparison with IVUS data obtained in previous studies involving shorter lesions shows a higher neointimal net volume obstruction for both the SES and PES in more complex lesions, and this was particularly evident for the PES. The difference in neointimal hyperplasia observed between the SES and the PES in the present study, however, does not translate into higher rates of angiographic in-stent and in-segment restenosis.
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